BILE ACID CONJUGATION IMBALANCE FOR DIFFERENTIATING DRUG-INDUCED FROM NON-DRUG-INDUCED LIVER INJURY

Authors

  • Johnson Okpe Centre for Civil-Military Cooperation (CIMICO), Abuja, Nigeria
  • Matthias Okwori Otakwu Ebonyi State University, Abakiliki, Ebonyi State, Nigeria

DOI:

https://doi.org/10.65327/bp.v12i2.2541

Keywords:

Drug-induced liver injury, bile acids, conjugation imbalance, glyco/tauro ratio, biomarkers

Abstract

Drug-induced liver injury (DILI) remains difficult to distinguish from other forms of liver injury because conventional biochemical markers lack etiological specificity. This study evaluated whether bile acid conjugation patterns could provide additional discriminatory value. A secondary-data-based observational comparative analysis was conducted using 120 patients with DILI, 49 with non-drug-induced liver injury, and 25 healthy controls from a publicly available Mendeley source. Major bile acid measures included total, conjugated, glycoconjugated, tauroconjugated, and unconjugated bile acids together with derived ratios. Descriptive statistics, independent-samples t-tests, Pearson correlation, and simple binary logistic regression were applied. Absolute concentrations of total bile acids and major conjugated bile acid fractions were broadly similar between DILI and non-DILI groups. However, the glycine-to-taurine ratio was significantly higher in DILI, whereas the conjugated-to-unconjugated ratio was significantly lower. TSLCA, αMCA, HyoDCA, and SLCA were also significantly higher in DILI. Strong positive correlations were observed among conjugated, glycoconjugated, tauroconjugated, and total bile acids. Logistic regression further showed that the glyco/tauro ratio and conjugated/unconjugated ratio were significantly associated with DILI status. These findings suggest that relative bile acid conjugation patterns may provide more useful discriminatory information than absolute bile acid concentrations for differentiating DILI from non-DILI, although further validation in larger independent cohorts is required.

 

Downloads

Download data is not yet available.

References

Alamoudi, J. A., Li, W., Gautam, N., Olivera, M., Meza, J., Mukherjee, S., & Alnouti, Y. (2021). Bile acid indices as biomarkers for liver diseases I: Diagnostic markers. World journal of hepatology, 13(4), 433.

Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., ... & Aithal, G. P. (2019). Drug-induced liver injury. Nature reviews Disease primers, 5(1), 58.

Atallah, E., Freixo, C., Alvarez-Alvarez, I., Cubero, F. J., Gerbes, A. L., Kullak-Ublick, G. A., & Aithal, G. P. (2021). Biomarkers of idiosyncratic drug-induced liver injury (DILI)-a systematic review. Expert Opinion on Drug Metabolism & Toxicology, 17(11), 1327-1343.

Azer, S. A., & Hasanato, R. (2021). Use of bile acids as potential markers of liver dysfunction in humans: A systematic review. Medicine, 100(41), e27464.

Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., & Reddy, K. R. (2021). ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. American Journal of Gastroenterology, 116(5), 878-898.

Cheng, X., Zhu, J. L., Li, Y., Luo, W. W., Xiang, H. R., Zhang, Q. Z., & Peng, W. X. (2022). Serum biomarkers of isoniazid‐induced liver injury: aminotransferases are insufficient, and OPN, L‐FABP and HMGB1 can be promising novel biomarkers. Journal of Applied Toxicology, 42(3), 516-528.

Farooqui, N., & Elhence, A. (2022). A current understanding of bile acids in chronic liver disease. Journal of clinical and experimental hepatology, 12(1), 155-173.

Gochfeld, M. (2017). Sex differences in human and animal toxicology: toxicokinetics. Toxicologic pathology, 45(1), 172-189.

Grove, J., Monte, M., Tran, T. D. B., Aithal, G., Li, D., & Stephens, C. (2026). Plasma bile acid profile as a biomarker for drug-induced liver injury (Version 1) [Data set]. Mendeley Data. https://doi.org/10.17632/sf6w9yyvnj.1

Hassan, M., Kansky, B., Sudhakar, H., El-Feki, I., Nguyen, T., & Lopera, S. (2025). Detection to prediction: biomarkers in severe drug-induced liver injury. Ameri J Clin Med Re: AJCMR-224, 13.

Hosack, T., Damry, D., & Biswas, S. (2023). Drug-induced liver injury: a comprehensive review. Therapeutic advances in gastroenterology, 16, 17562848231163410.

Luo, L., Aubrecht, J., Li, D., Warner, R. L., Johnson, K. J., Kenny, J., & Colangelo, J. L. (2018). Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PloS one, 13(3), e0193824.

Ma, Z., Wang, X., Yin, P., Wu, R., Zhou, L., Xu, G., & Niu, J. (2019). Serum metabolome and targeted bile acid profiling reveals potential novel biomarkers for drug-induced liver injury. Medicine, 98(31), e16717.

Mireault, M., Rose, C. F., Karvellas, C. J., & Sleno, L. (2024). Perturbations in human bile acid profiles following drug‐induced liver injury investigated using semitargeted high‐resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 38(9), e9731.

Monte, M. J., Tran, T. D. B., Grove, J. I., Li, D., Stephens, C., Lucena, M. I., ... & Aithal, G. P. (2026). Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury. EBioMedicine, 126.

Quintás, G., Martínez-Sena, T., Conde, I., Pareja Ibars, E., Kleinjans, J., & Castell, J. V. (2021). Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. Archives of toxicology, 95(9), 3049-3062.

Saran, C., & Brouwer, K. L. (2023). Hepatic bile acid transporters and drug-induced hepatotoxicity. Toxicologic pathology, 51(7-8), 405-413.

Saville, E., Wells, G., Farrell, L., Naisbitt, D. J., & Meng, X. (2026). Insights into the Biochemical and Immune Mechanisms in Drug-Induced Liver Injury Pathogenesis. Chemical research in toxicology, 39(3), 267.

Shi, Y., Gao, Y., Van Parys, M., Miller, D., Milanowski, D., Dean, B., & Liang, X. (2018). Definitive profiling of plasma bile acids as potential biomarkers for human liver diseases using UPLC–HRMS. Bioanalysis, 10(12), 917-932.

Tao, W., Fan, Q., & Wei, J. (2024). Gut–liver axis as a therapeutic target for drug-induced liver injury. Current Issues in Molecular Biology, 46(2), 1219-1236.

Yu, S., Wang, S., Li, P., Zheng, H., Jing, J., He, T., ... & Wang, R. (2025). Integrated analysis of serum and fecal metabolites reveals the role of bile acid metabolism in drug-induced liver injury: implications for diagnostic and prognostic biomarkers. Journal of Clinical and Translational Hepatology, 13(8), 619.

Zhao, S., Fu, H., Zhou, T., Cai, M., Huang, Y., Gan, Q., ... & Xie, Q. (2022). Alteration of bile acids and omega-6 PUFAs are correlated with the progression and prognosis of drug-induced liver injury. Frontiers in Immunology, 13, 772368.

Downloads

Published

2026-05-30

How to Cite

Johnson Okpe, & Matthias Okwori Otakwu. (2026). BILE ACID CONJUGATION IMBALANCE FOR DIFFERENTIATING DRUG-INDUCED FROM NON-DRUG-INDUCED LIVER INJURY. International Journal For Research In Biology & Pharmacy, 12(2), 88–98. https://doi.org/10.65327/bp.v12i2.2541